kaiser glp-1 coverage weight loss A New Medicare Option for Drugs: What Older Americans Should Know Perspectives from Employers on the

Existing GLP-1 therapies function as drugs that make patients eat less, while retatrutide, by also targeting the glucagon receptor, adds a function that enables the body to burn more fat

doi: 10.3390/antiox14040476 62

ESSENCE Phase 3 semaglutide in MASH data supported FDA approval in March 2024 , creating a premium pricing tier in a disease category with USD 17.4 billion addressable market and no prior approved pharmacotherapy

Side effects followed the pattern typical of incretin-based therapies

The GIP receptor activation in both tirzepatide and retatrutide appears to contribute substantially to insulin sensitization in fat tissue, which may explain why both outperform semaglutide on this metric